Payment overview · 2025
General Payments
$357.15
19 reported records · 14 companies
Healthcare provider profile · identity verified
Miranda Brown
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BAY CITY, MI · NPI 1194477182
Verified facts
What the public records show
CMS Open Payments records show Miranda Brown received $357.15 in general payments during 2025 across 19 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 10.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.67 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.37 | 9.1% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $31.77 | 8.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.09 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.65 | 8.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.75 | 8.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.34 | 6.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.10 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.53 | 6.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.36 | 6.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.51 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.78 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.33 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.90 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.15 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.37 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 80 |
| Lisinopril | Lisinopril | 280 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 59 |
| Metformin Hcl | Metformin Hcl | 204 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 37 |
| Gabapentin | Gabapentin | 188 | 37 |
| Omeprazole | Omeprazole | 148 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 43 |
| Losartan Potassium | Losartan Potassium | 116 | 28 |
| Jardiance | Empagliflozin | 101 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 20 |
| Famotidine | Famotidine | 92 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 19 |
| Trulicity | Dulaglutide | 80 | 12 |
| Eliquis | Apixaban | 75 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 12 |
| Montelukast Sodium | Montelukast Sodium | 68 | 14 |
| Simvastatin | Simvastatin | 68 | 17 |
| Furosemide | Furosemide | 67 | 13 |
| Potassium Chloride | Potassium Chloride | 67 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 14 |
| Allopurinol | Allopurinol | 59 | suppressed |
| Carvedilol | Carvedilol | 59 | suppressed |
| Ozempic | Semaglutide | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 20 |
| Glipizide | Glipizide | 54 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 13 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 11 |
| Meloxicam | Meloxicam | 45 | 16 |
| Buspirone Hcl | Buspirone Hcl | 44 | 11 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Baclofen | Baclofen | 40 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | 13 |
| Metformin Hcl Er | Metformin Hcl | 34 | 14 |
| Naproxen | Naproxen | 34 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nystatin | Nystatin | 12 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.15 · 19 records | SANOFI-AVENTIS U.S. LLC | AIRSUPRA, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, INGREZZA, MAVYRET, MOUNJARO, NEXPLANON, ROTATEQ, TZIELD, VAXNEUVANCE, Veozah, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error